Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Conditional ablation of Ikkb inhibits melanoma tumor development in mice

(2010) Jinming Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2

(2010) Sergio E. Alvarez et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic RAF: a brief history of time

(2010) David Solit et al.   Pigment Cell & Melanoma Research

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

(2010) John T. Lee et al.   Pigment Cell & Melanoma Research

Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts

(2009) D. Kapitonov et al.   CANCER RESEARCH

Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2

(2009) H Christian Reinhardt et al.   CURRENT OPINION IN CELL BIOLOGY

Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape

(2009) Aleksandar Sekulic et al.   MAYO CLINIC PROCEEDINGS

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

(2009) M. A. Hardwicke et al.   MOLECULAR CANCER THERAPEUTICS

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma

(2009) Supriya Gaitonde et al.   Pigment Cell & Melanoma Research

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

(2009) SubbaRao V. Madhunapantula et al.   Pigment Cell & Melanoma Research

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia

(2008) S. W. Paugh et al.   BLOOD

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

(2008) N. Rhodes et al.   CANCER RESEARCH

Targeting SphK1 as a New Strategy against Cancer

(2008) Dai Shida et al.   CURRENT DRUG TARGETS

The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways

(2008) J. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SKAP55 modulates T cell antigen receptor-induced activation of the Ras–Erk–AP1 pathway by binding RasGRP1

(2007) Karena A. Kosco et al.   MOLECULAR IMMUNOLOGY